What Is Selank Peptide? Structure, Mechanisms, and Research

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.

Its amino acid sequence — Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) — is derived from tuftsin, an endogenous immunomodulatory tetrapeptide, with a three-residue extension added to improve metabolic stability.

What draws researchers to Selank isn’t a single mechanism. Three distinct pathways have been studied in preclinical models: GABAergic modulation, neurotrophin regulation, and immunomodulatory activity inherited from its tuftsin lineage.

This article covers each of those mechanisms, the study models where they’ve been examined, and what the published literature says about how they interact.

For research use only. All products and compounds discussed are intended strictly for in vitro and preclinical laboratory research.

What Is Selank Peptide?

Selank belongs to a class of regulatory peptides developed from endogenous sequences. Its design — extending tuftsin’s four-residue backbone with Pro-Gly-Pro — gave researchers a compound with longer serum stability than the native tetrapeptide, making it more tractable for laboratory study.

It is also known by its experimental designation TP-7.

Origins and Development

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide cleaved from the Fc region of immunoglobulin G. It was identified as an immunostimulant in the 1970s and has since been studied for anti-inflammatory, antimicrobial, and antitumor activity, as reviewed in Siebert et al. (2017).^[1]

Selank was synthesized by appending a Pro-Gly-Pro tripeptide to tuftsin’s C-terminus. That modification significantly extends the compound’s resistance to enzymatic degradation compared to the parent molecule — a property relevant for any researcher designing time-course studies.

Structural Profile

Selank carries the sequence TKPRPGP across seven amino acid residues, with a molecular formula of C₃₃H₅₇N₁₁O₉ and a molecular weight of approximately 751.9 Da.

Understanding how the polarity and charge distribution of those residues affects binding behavior is worth reviewing alongside foundational material on polar and nonpolar amino acids before designing binding or stability assays.

Lyophilized Selank is stable for extended periods under proper cold storage conditions, making it suitable for multi-experiment research protocols.

Featured Product: Buy N-Acetyl Selank for in vitro laboratory research applications.

Selank’s Three Studied Research Mechanisms

Selank occupies an unusual position in neuropeptide research: it has been examined across three mechanistic axes that are largely independent in the literature. Most papers address one of them in depth.

The three are GABAergic system modulation, BDNF-related neurotrophin regulation, and immunomodulatory activity inherited from tuftsin.

GABAergic System Modulation

The most extensively studied mechanism involves Selank’s interaction with the GABAergic system — the primary inhibitory neurotransmitter pathway in the mammalian central nervous system.

Volkova et al. (2016) analyzed changes in the expression of 84 genes involved in neurotransmission in rat frontal cortex tissue. One hour after Selank application at 300 µg/kg, 45 genes showed measurable expression changes. At the three-hour mark, 22 genes remained altered. The pattern of change showed positive correlation with GABA-treated controls, pointing toward allosteric modulation of GABA-A receptor activity as a probable mechanism.^[2]

Vyunova et al. (2018) examined that allosteric interaction directly using radioligand-receptor methods. Selank was shown to affect [³H]GABA binding in a concentration-dependent manner consistent with positive allosteric modulation of GABA-A receptors — a mechanistically distinct profile from classical benzodiazepines despite some behavioral overlap in anxiety models.^[3]

A follow-up study by Filatova et al. (2017) tested Selank in IMR-32 neuroblastoma cells alongside GABA and olanzapine. Selank alone produced no direct changes in GABAergic gene mRNA levels in that cell line. When combined with GABA, Selank nearly fully suppressed the gene expression changes GABA produced on its own. The authors interpreted this as evidence that Selank affects GABA receptor interactions rather than acting as a direct transcriptional modulator — a distinction with implications for how labs design mechanistic assays.^[4]

BDNF and Neurotrophin Regulation

Brain-derived neurotrophic factor (BDNF) is a well-characterized regulator of synaptic plasticity and neuronal survival. Selank’s influence on BDNF expression has been studied in rat brain tissue across multiple models.

Kolik et al. (2019) examined BDNF content in the hippocampus and prefrontal cortex of rats exposed to chronic ethanol, followed by seven-day Selank application. Selank prevented the ethanol-induced increase in BDNF content in both brain regions in ex vivo analysis. The authors concluded that neurotrophin pathways related to BDNF production are involved in Selank’s mechanism of action — though the directionality of that involvement appears context-dependent, with BDNF modulation differing between basal and stress-exposed conditions.^[5]

Earlier intranasal application studies (referenced in the Filatova and Kolik papers) had established that Selank can regulate BDNF expression in the rat hippocampus, which led to the neuroplasticity-related research focus seen in subsequent work.

For laboratories studying neurotrophin biology, this BDNF-modulatory profile makes Selank a potentially useful tool compound in models examining synaptic signaling or memory-related endpoints.

Immunomodulatory Activity

Selank inherits immunomodulatory properties from tuftsin — and researchers have begun characterizing how that activity manifests at the gene expression level.

Kolomin et al. (2013) examined the temporal dynamics of inflammation-related gene expression in mouse spleen following a single intraperitoneal injection of Selank at 100 µg/kg. C3 mRNA levels dropped approximately threefold within 30 minutes of application. Wave-like alterations in Casp1, Il2rg, and Xcr1 expression were observed across the 90-minute observation window. Notably, Selank’s short fragment Gly-Pro produced similar expression profiles for most genes tested — pointing to the dipeptide’s contribution to the full compound’s immunomodulatory effect.^[6]

This immune axis is where Selank’s research profile diverges most sharply from structurally similar neuropeptides. Researchers focused on Th1/Th2 balance, complement regulation, or cytokine signaling may find Selank a useful comparator compound alongside immune-focused peptides like thymulin.

How Selank Compares to Related Research Peptides

Selank is rarely studied in isolation from Semax, a structurally unrelated neuropeptide developed at the same institute around the same period.

Both compounds share the property of inhibiting enzymes responsible for breaking down enkephalins and other endogenous regulatory peptides. That shared activity on enkephalin metabolism creates some mechanistic overlap — but the two peptides differ in their amino acid sequences, receptor targets, and documented gene expression signatures.

Selank vs. Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH analog, not a tuftsin derivative. Its primary research focus has been neuroprotection, cognitive function, and BDNF upregulation — with a body of literature that is largely separate from Selank’s GABAergic and immunomodulatory work.

The two peptides are sometimes placed in the same experimental battery precisely because their mechanisms differ: using both allows researchers to isolate specific pathway contributions in complex behavioral or cellular models.

For a detailed breakdown of how the two compounds compare structurally and mechanistically, see the Selank vs. Semax comparison.

Selank in Laboratory Research Settings

The breadth of Selank’s studied mechanisms has resulted in its use across a range of experimental contexts — from in vitro gene expression work to ex vivo brain tissue analysis to preclinical stress models.

The table below summarizes the primary research areas represented in the published literature.

Research Area	Model Systems	Observed Focus
GABAergic neurotransmission	Rat frontal cortex, IMR-32 neuroblastoma cells	Gene expression profiling, receptor binding
Neurotrophin regulation	Ex vivo rat hippocampus and prefrontal cortex	BDNF modulation under ethanol and basal conditions
Immunomodulation	Mouse spleen (preclinical, in vivo)	Inflammation-related gene dynamics (C3, Casp1, Il2rg, Xcr1)
Stress response modeling	Wistar rat chronic foot-shock model	Liver morphology, degenerative change attenuation
Memory and cognition	Outbred rat object recognition assay	Ethanol-induced memory impairment

Research-Grade Selank: What to Look For

Quality varies across suppliers, and the mechanistic specificity of Selank research makes purity non-negotiable.

For in vitro or ex vivo work, any contaminant at the peptide level can produce confounding signal — particularly in gene expression assays where the compound’s effects are measured at very low concentrations.

Quality and Documentation Standards

BioLongevity Labs supplies Selank at greater than 99% purity, confirmed by HPLC and LC-MS analysis from three independent certified laboratories. Every batch ships with a full Certificate of Analysis documenting purity, molecular confirmation, and analytical methodology.

If you’re evaluating a supplier’s COA for the first time, the guide to reading peptide COAs covers what to look for and what gaps in documentation signal. For a broader overview of what third-party testing actually involves, see the third-party tested peptides resource.

Selank is available from BioLongevity Labs in lyophilized vial format, manufactured in a U.S. GMP-certified facility.

Closing Thoughts

Selank’s research profile is harder to summarize than most peptides precisely because it doesn’t reduce to a single mechanism.

The GABAergic work, the BDNF studies, and the immunomodulatory literature each represent distinct research threads developed mostly independently. Understanding how they relate — or whether they’re even causally linked — remains an open question in the field.

For labs designing experiments around anxiety models, neurotrophin biology, or immune signaling, that multi-axis profile is what makes Selank worth understanding in depth before committing to an experimental design.

Researchers sourcing Selank for in vitro studies can review documentation and place orders through the BioLongevity Labs Selank product page. All products are for research use only.

Research Use Only Disclaimer: All products and compounds discussed in this article are intended strictly for in vitro and preclinical laboratory research purposes. Researchers are responsible for complying with all applicable regulations in their jurisdiction.

References

1. Siebert, A., Gensicka-Kowalewska, M., Cholewinski, G., & Dzierzbicka, K. (2017). Tuftsin – Properties and Analogs. In Current Medicinal Chemistry (Vol. 24, Issue 34). Bentham Science Publishers Ltd. https://doi.org/10.2174/0929867324666170725140826
2. Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. In Frontiers in Pharmacology (Vol. 7). Frontiers Media SA. https://doi.org/10.3389/fphar.2016.00031
3. Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. In Protein & Peptide Letters (Vol. 25, Issue 10, pp. 914–923). Bentham Science Publishers Ltd. https://doi.org/10.2174/0929866525666180925144642
4. Filatova, E., Kasian, A., Kolomin, T., Rybalkina, E., Alieva, A., Andreeva, L., Limborska, S., Myasoedov, N., Pavlova, G., Slominsky, P., & Shadrina, M. (2017). GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. In Frontiers in Pharmacology (Vol. 8). Frontiers Media SA. https://doi.org/10.3389/fphar.2017.00089
5. Kolik, L. G., Nadorova, A. V., Antipova, T. A., Kruglov, S. V., Kudrin, V. S., & Durnev, A. D. (2019). Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. In Bulletin of Experimental Biology and Medicine (Vol. 167, Issue 5, pp. 641–644). Springer Science and Business Media LLC. https://doi.org/10.1007/s10517-019-04588-9
6. Kolomin, T., Morozova, M., Volkova, A., Shadrina, M., Andreeva, L., Slominsky, P., Limborska, S., & Myasoedov, N. (2014). The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. In Molecular Immunology (Vol. 58, Issue 1, pp. 50–55). Elsevier BV. https://doi.org/10.1016/j.molimm.2013.11.002